These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17704566)

  • 1. Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV.
    Oefner C; Pierau S; Schulz H; Dale GE
    Acta Crystallogr D Biol Crystallogr; 2007 Sep; 63(Pt 9):975-81. PubMed ID: 17704566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of neprilysin with various specific and potent inhibitors.
    Oefner C; Roques BP; Fournie-Zaluski MC; Dale GE
    Acta Crystallogr D Biol Crystallogr; 2004 Feb; 60(Pt 2):392-6. PubMed ID: 14747736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon.
    Oefner C; D'Arcy A; Hennig M; Winkler FK; Dale GE
    J Mol Biol; 2000 Feb; 296(2):341-9. PubMed ID: 10669592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; McClure LD; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soeller WC; Soglia CB; Treadway JL; VanVolkenburg MA; Wang H; Wilder DC; Olson TV
    J Med Chem; 2006 Jun; 49(11):3068-76. PubMed ID: 16722626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity.
    Ueda T; Tomita K; Notsu Y; Ito T; Fumoto M; Takakura T; Nagatome H; Takimoto A; Mihara S; Togame H; Kawamoto K; Iwasaki T; Asakura K; Oshima T; Hanasaki K; Nishimura S; Kondo H
    J Am Chem Soc; 2009 May; 131(17):6237-45. PubMed ID: 19361194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
    Madar DJ; Kopecka H; Pireh D; Yong H; Pei Z; Li X; Wiedeman PE; Djuric SW; Von Geldern TW; Fickes MG; Bhagavatula L; McDermott T; Wittenberger S; Richards SJ; Longenecker KL; Stewart KD; Lubben TH; Ballaron SJ; Stashko MA; Long MA; Wells H; Zinker BA; Mika AK; Beno DW; Kempf-Grote AJ; Polakowski J; Segreti J; Reinhart GA; Fryer RM; Sham HL; Trevillyan JM
    J Med Chem; 2006 Oct; 49(21):6416-20. PubMed ID: 17034148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin.
    Taldone T; Zito SW; Talele TT
    Bioorg Med Chem Lett; 2008 Jan; 18(2):479-84. PubMed ID: 18068977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulation and degradation of GIP and GLP-1.
    Deacon CF
    Horm Metab Res; 2004; 36(11-12):761-5. PubMed ID: 15655705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.
    Longenecker KL; Stewart KD; Madar DJ; Jakob CG; Fry EH; Wilk S; Lin CW; Ballaron SJ; Stashko MA; Lubben TH; Yong H; Pireh D; Pei Z; Basha F; Wiedeman PE; von Geldern TW; Trevillyan JM; Stoll VS
    Biochemistry; 2006 Jun; 45(24):7474-82. PubMed ID: 16768443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
    Fukushima H; Hiratate A; Takahashi M; Saito M; Munetomo E; Kitano K; Saito H; Takaoka Y; Yamamoto K
    Bioorg Med Chem; 2004 Dec; 12(23):6053-61. PubMed ID: 15519151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
    Herman GA; Bergman A; Liu F; Stevens C; Wang AQ; Zeng W; Chen L; Snyder K; Hilliard D; Tanen M; Tanaka W; Meehan AG; Lasseter K; Dilzer S; Blum R; Wagner JA
    J Clin Pharmacol; 2006 Aug; 46(8):876-86. PubMed ID: 16855072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors.
    Ahn JH; Shin MS; Jun MA; Jung SH; Kang SK; Kim KR; Rhee SD; Kang NS; Kim SY; Sohn SK; Kim SG; Jin MS; Lee JO; Cheon HG; Kim SS
    Bioorg Med Chem Lett; 2007 May; 17(9):2622-8. PubMed ID: 17331715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
    Kirby M; Yu DM; O'Connor S; Gorrell MD
    Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.
    Malm-Erjefält M; Bjørnsdottir I; Vanggaard J; Helleberg H; Larsen U; Oosterhuis B; van Lier JJ; Zdravkovic M; Olsen AK
    Drug Metab Dispos; 2010 Nov; 38(11):1944-53. PubMed ID: 20709939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1.
    Green BD; Liu HK; McCluskey JT; Duffy NA; O'Harte FP; McClenaghan NH; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):563-9. PubMed ID: 16050949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog.
    Rasmussen HB; Branner S; Wiberg FC; Wagtmann N
    Nat Struct Biol; 2003 Jan; 10(1):19-25. PubMed ID: 12483204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structural comparison of the bacterial PepX and human DPP-IV reveals sites for the design of inhibitors of PepX activity.
    Rigolet P; Xi XG; Rety S; Chich JF
    FEBS J; 2005 Apr; 272(8):2050-9. PubMed ID: 15819895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.